Volume Alert - ABBV 63.79 Abbvie Inc. Common Stock $ABBV Hit a high today of 64.06 Closing the day 11/10/14 at 63.79 +2.29 +3.72% With a day low of 61.87 and a total volume of 9,525,557.
ABBV Recent Posts: http://investorshangout.com/AbbVie-Inc-ABBV-90091/
ABBV Abbvie Inc. Common Stock Recent Headline News
Repros Soars on Positive FDA Meeting Regarding Androxa - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 4:20PM CST
Shares of Repros Therapeutics (RPRX) shot up 56.9% following a successful meeting with the FDA regarding Androxal.
BIIB: 327.87 (+7.12), RPRX: 9.22 (-0.90), ABBV: 63.79 (+2.29), AMAG: 34.91 (-0.04)
Shire CEO Looks Ahead To Independent Future
at Investor's Business Daily - Mon Nov 10, 3:46PM CST
Flemming Ornskov has been at Shire for only 18 months, but his term has been quite an adventure already. In January, he closed the Anglo-Irish drugmaker's biggest acquisition, buying U.S. biotech ViroPharma for $4.2 billion. That brought Shire (SHPG)...
BIIB: 327.87 (+7.12), GILD: 107.02 (+0.57), SHPG: 200.98 (+2.40), ABBV: 63.79 (+2.29), CELG: 108.01 (+1.56)
Merck Reports Interim Data on Hepatitis C Virus Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 3:45PM CST
Merck (MRK) presented interim data from a proof-of-concept study on its fixed-dose combination regimen - grazoprevir/elbasvir - in combination with Gilead's Sovaldi.
AGN: 195.24 (-0.76), GILD: 107.02 (+0.57), MRK: 58.81 (-0.53), ABBV: 63.79 (+2.29)
Emergent BioSolutions Beats on Q3 Earnings, Guidance Up - Analyst Blog
Lopamudra Bhattacharya - Zacks Investment Research - Mon Nov 10, 11:30AM CST
Emergent BioSolutions reported third quarter earnings of 67 cents per share.
AGN: 195.24 (-0.76), EBS: 23.95 (unch), ABAX: 52.94 (+1.31), ABBV: 63.79 (+2.29)
Merck Down On Hepatitis C Data; Gilead Rises
at Investor's Business Daily - Mon Nov 10, 10:14AM CST
Big pharma Merck (MRK) was down nearly 2% on the stock market today after the latest data from its hepatitis C pipeline underwhelmed the Street. On Sunday at the annual conference of the American Association for the Study of Liver Disease, Merck...
JNJ: 108.82 (+0.62), GILD: 107.02 (+0.57), ACHN: 12.85 (+2.74), MRK: 58.81 (-0.53), ABBV: 63.79 (+2.29), BMY: 58.81 (+0.49)
Buyside Buzz on Gilead, Regulus From This Year's Liver Meeting
at The Street - Mon Nov 10, 9:40AM CST
Here's a quick sketch of the Wall Street gossip mill emerging from the 'Liver Meeting.'
GILD: 107.02 (+0.57), ACHN: 12.85 (+2.74), RGLS: 20.91 (-1.17), ABBV: 63.79 (+2.29)
Merck triple therapy HCV candidate fails as a four-week regimen
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 6:49AM CST
JNJ: 108.82 (+0.62), GILD: 107.02 (+0.57), CNAT: 7.06 (+0.21), MRK: 58.81 (-0.53), LGND: 55.68 (+1.74), RGLS: 20.91 (-1.17), ABBV: 63.79 (+2.29), BMY: 58.81 (+0.49), ENTA: 44.14 (+0.81)
Merck's Shortened Hep C Regimens Fall Short of Cure-Rate Goal
at The Street - Sun Nov 09, 5:23PM CST
A triple therapy combining two experimental Merck drugs with Gilead's Sovaldi yielded interim hepatitis C cure rates for ranging from 80% to 87% following six to eight weeks of treatment.
GILD: 107.02 (+0.57), MRK: 58.81 (-0.53), ABBV: 63.79 (+2.29)
Bristol-Myers presents data on HCV Trio regimen
Seeking Alpha - at Seeking Alpha - Sun Nov 09, 5:04PM CST
JNJ: 108.82 (+0.62), GILD: 107.02 (+0.57), CNAT: 7.06 (+0.21), MRK: 58.81 (-0.53), LGND: 55.68 (+1.74), RGLS: 20.91 (-1.17), ABBV: 63.79 (+2.29), BMY: 58.81 (+0.49), ENTA: 44.14 (+0.81)
Bristol-Myers presents data on shorter regimen HCV drug combo
Seeking Alpha - at Seeking Alpha - Sun Nov 09, 4:37PM CST
JNJ: 108.82 (+0.62), GILD: 107.02 (+0.57), CNAT: 7.06 (+0.21), MRK: 58.81 (-0.53), LGND: 55.68 (+1.74), RGLS: 20.91 (-1.17), ABBV: 63.79 (+2.29), BMY: 58.81 (+0.49), ENTA: 44.14 (+0.81)
Achillion presents HCV data at The Liver Meeting
Seeking Alpha - at Seeking Alpha - Sun Nov 09, 4:06PM CST
JNJ: 108.82 (+0.62), GILD: 107.02 (+0.57), ACHN: 12.85 (+2.74), CNAT: 7.06 (+0.21), MRK: 58.81 (-0.53), LGND: 55.68 (+1.74), RGLS: 20.91 (-1.17), ABBV: 63.79 (+2.29), BMY: 58.81 (+0.49), ENTA: 44.14 (+0.81)
Google's "Cancer Pill": Revolutionary or Ridiculous?
Leo Sun, The Motley Fool - Motley Fool - Sun Nov 09, 1:24PM CST
Google recently unveiled one of its most ambitious healthcare projects ever -- a "smart pill" which scans for cancer cells and other health problems. The pill is loaded with nanoparticles, which are roughly 1/2,000th the size of a red blood cell,...
ABBV: 63.79 (+2.29), GOOGL: 558.23 (+6.41), GOOG: 547.49 (+6.48), ORCL: 40.45 (+0.51), NVS: 92.63 (+0.87)
3 Biotech Stocks to Watch in November
Motley Fool Staff - Motley Fool - Sat Nov 08, 10:03AM CST
Investing in biotech companies can be tricky, especially for investors who don't have a scientific background or who don't completely understand the process of bringing new drugs to the marketplace. Fortunately, the Fool is here to help. We asked...
AVNR: 13.22 (+0.20), SGEN: 36.90 (+0.85), GILD: 107.02 (+0.57), ABBV: 63.79 (+2.29), GSK: 45.16 (+0.25)
Gilead (GILD) Submits HIV Combination Drug for FDA Review - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 5:50PM CST
Gilead Sciences, Inc. announced that it has submitted a New Drug Application to the FDA for its tenofovir alafenamide-based single tablet regimen.
AGN: 195.24 (-0.76), JNJ: 108.82 (+0.62), GILD: 107.02 (+0.57), ABBV: 63.79 (+2.29)
Novartis' (NVS) LBH589 Gets Unfavorable FDA Panel Opinion - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 4:20PM CST
Novartis (NVS) received disappointing news when the FDA's Oncologic Drugs Advisory Committee (ODAC) did not recommend its pipeline candidate LBH589.
AGN: 195.24 (-0.76), ABBV: 63.79 (+2.29), BMY: 58.81 (+0.49), NVS: 92.63 (+0.87)
AstraZeneca (AZN) Misses on Q3 Earnings, Raises Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 2:20PM CST
AstraZeneca (AZN) reported third-quarter 2014 core earnings of $1.05 per ADS that missed the Zacks Consensus Estimate by a penny.
AGN: 195.24 (-0.76), AZN: 73.21 (+0.33), ABBV: 63.79 (+2.29), AEGR: 21.57 (-0.01)
One Factor Driving AbbVie (ABBV) Stock Down Today
at The Street - Fri Nov 07, 10:50AM CST
Shares of AbbVie (ABBV) are down after the company was downgraded to 'market perform' to 'outperform' at BMO Capital Markets earlier on Friday.
ABBV: 63.79 (+2.29)
SurModics Beats on Q4 Earnings, Issues Fiscal 2015 Outlook - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 9:10AM CST
SurModics, Inc.???s fourth-quarter fiscal 2014 adjusted earnings of 26 cents per share beat the Zacks Consensus Estimate by a penny.
AGN: 195.24 (-0.76), SRDX: 20.86 (+0.42), ABAX: 52.94 (+1.31), ABBV: 63.79 (+2.29)
Why AbbVie Inc.'s Game-Changing New Drug Could Be a Serious Threat to Gilead Sciences Inc.
George Budwell, The Motley Fool - Motley Fool - Fri Nov 07, 7:45AM CST
The patent cliff might have decimated revenues in the world of Big Pharma, but it has also led to an unprecedented level of innovation within the industry. In the coming years, for example, we should see four to five new types of drugs that are...
JNJ: 108.82 (+0.62), ESRX: 77.99 (+0.12), GILD: 107.02 (+0.57), ABBV: 63.79 (+2.29), BMY: 58.81 (+0.49), ENTA: 44.14 (+0.81)
Global Cognitive Impairment Therapeutics Pipeline Review 2014 - 53 Drug Profiles from 23 Leading Pharma Companies
M2 - Fri Nov 07, 6:02AM CST
Research and Markets (http://www.researchandmarkets.com/research/jxpc52/cognitive) has announced the addition of the "Cognitive Impairment - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cognitive Impairment, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cognitive Impairment and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bristol-Myers Squibb Company - F. Hoffmann-La Roche Ltd. - AstraZeneca PLC - Merck & Co., Inc. - Panacea Pharmaceuticals, Inc. - Pfizer Inc. - Teva Pharmaceutical Industries Limited - Shire Plc - Evotec AG - Suven Life Sciences Ltd. - AGY Therapeutics, Inc. - Cardax Pharmaceuticals, Inc. - Siena Biotech S.p.A. - Virogenomics, Inc. - Dart NeuroScience LLC - Omeros Corporation - Intra-Cellular Therapies, Inc. - Heptares Therapeutics Ltd. - Pacific Northwest Biotechnology, LLC - Vicore Pharma AB - Pherin Pharmaceuticals, Inc. - AbbVie Inc. - Saniona AB For more information visit http://www.researchandmarkets.com/research/jxpc52/cognitive
SHPG: 200.98 (+2.40), PFE: 30.20 (+0.28), MRK: 58.81 (-0.53), AZN: 73.21 (+0.33), TEVA: 58.04 (+0.34), ITCI: 15.74 (+0.48), ABBV: 63.79 (+2.29), BMY: 58.81 (+0.49), OMER: 17.49 (+0.12)
ABBV Recent Posts: http://investorshangout.com/AbbVie-Inc-ABBV-90091/
ABBV Abbvie Inc. Common Stock Recent Headline News
Repros Soars on Positive FDA Meeting Regarding Androxa - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 4:20PM CST
Shares of Repros Therapeutics (RPRX) shot up 56.9% following a successful meeting with the FDA regarding Androxal.
BIIB: 327.87 (+7.12), RPRX: 9.22 (-0.90), ABBV: 63.79 (+2.29), AMAG: 34.91 (-0.04)
Shire CEO Looks Ahead To Independent Future
at Investor's Business Daily - Mon Nov 10, 3:46PM CST
Flemming Ornskov has been at Shire for only 18 months, but his term has been quite an adventure already. In January, he closed the Anglo-Irish drugmaker's biggest acquisition, buying U.S. biotech ViroPharma for $4.2 billion. That brought Shire (SHPG)...
BIIB: 327.87 (+7.12), GILD: 107.02 (+0.57), SHPG: 200.98 (+2.40), ABBV: 63.79 (+2.29), CELG: 108.01 (+1.56)
Merck Reports Interim Data on Hepatitis C Virus Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 3:45PM CST
Merck (MRK) presented interim data from a proof-of-concept study on its fixed-dose combination regimen - grazoprevir/elbasvir - in combination with Gilead's Sovaldi.
AGN: 195.24 (-0.76), GILD: 107.02 (+0.57), MRK: 58.81 (-0.53), ABBV: 63.79 (+2.29)
Emergent BioSolutions Beats on Q3 Earnings, Guidance Up - Analyst Blog
Lopamudra Bhattacharya - Zacks Investment Research - Mon Nov 10, 11:30AM CST
Emergent BioSolutions reported third quarter earnings of 67 cents per share.
AGN: 195.24 (-0.76), EBS: 23.95 (unch), ABAX: 52.94 (+1.31), ABBV: 63.79 (+2.29)
Merck Down On Hepatitis C Data; Gilead Rises
at Investor's Business Daily - Mon Nov 10, 10:14AM CST
Big pharma Merck (MRK) was down nearly 2% on the stock market today after the latest data from its hepatitis C pipeline underwhelmed the Street. On Sunday at the annual conference of the American Association for the Study of Liver Disease, Merck...
JNJ: 108.82 (+0.62), GILD: 107.02 (+0.57), ACHN: 12.85 (+2.74), MRK: 58.81 (-0.53), ABBV: 63.79 (+2.29), BMY: 58.81 (+0.49)
Buyside Buzz on Gilead, Regulus From This Year's Liver Meeting
at The Street - Mon Nov 10, 9:40AM CST
Here's a quick sketch of the Wall Street gossip mill emerging from the 'Liver Meeting.'
GILD: 107.02 (+0.57), ACHN: 12.85 (+2.74), RGLS: 20.91 (-1.17), ABBV: 63.79 (+2.29)
Merck triple therapy HCV candidate fails as a four-week regimen
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 6:49AM CST
JNJ: 108.82 (+0.62), GILD: 107.02 (+0.57), CNAT: 7.06 (+0.21), MRK: 58.81 (-0.53), LGND: 55.68 (+1.74), RGLS: 20.91 (-1.17), ABBV: 63.79 (+2.29), BMY: 58.81 (+0.49), ENTA: 44.14 (+0.81)
Merck's Shortened Hep C Regimens Fall Short of Cure-Rate Goal
at The Street - Sun Nov 09, 5:23PM CST
A triple therapy combining two experimental Merck drugs with Gilead's Sovaldi yielded interim hepatitis C cure rates for ranging from 80% to 87% following six to eight weeks of treatment.
GILD: 107.02 (+0.57), MRK: 58.81 (-0.53), ABBV: 63.79 (+2.29)
Bristol-Myers presents data on HCV Trio regimen
Seeking Alpha - at Seeking Alpha - Sun Nov 09, 5:04PM CST
JNJ: 108.82 (+0.62), GILD: 107.02 (+0.57), CNAT: 7.06 (+0.21), MRK: 58.81 (-0.53), LGND: 55.68 (+1.74), RGLS: 20.91 (-1.17), ABBV: 63.79 (+2.29), BMY: 58.81 (+0.49), ENTA: 44.14 (+0.81)
Bristol-Myers presents data on shorter regimen HCV drug combo
Seeking Alpha - at Seeking Alpha - Sun Nov 09, 4:37PM CST
JNJ: 108.82 (+0.62), GILD: 107.02 (+0.57), CNAT: 7.06 (+0.21), MRK: 58.81 (-0.53), LGND: 55.68 (+1.74), RGLS: 20.91 (-1.17), ABBV: 63.79 (+2.29), BMY: 58.81 (+0.49), ENTA: 44.14 (+0.81)
Achillion presents HCV data at The Liver Meeting
Seeking Alpha - at Seeking Alpha - Sun Nov 09, 4:06PM CST
JNJ: 108.82 (+0.62), GILD: 107.02 (+0.57), ACHN: 12.85 (+2.74), CNAT: 7.06 (+0.21), MRK: 58.81 (-0.53), LGND: 55.68 (+1.74), RGLS: 20.91 (-1.17), ABBV: 63.79 (+2.29), BMY: 58.81 (+0.49), ENTA: 44.14 (+0.81)
Google's "Cancer Pill": Revolutionary or Ridiculous?
Leo Sun, The Motley Fool - Motley Fool - Sun Nov 09, 1:24PM CST
Google recently unveiled one of its most ambitious healthcare projects ever -- a "smart pill" which scans for cancer cells and other health problems. The pill is loaded with nanoparticles, which are roughly 1/2,000th the size of a red blood cell,...
ABBV: 63.79 (+2.29), GOOGL: 558.23 (+6.41), GOOG: 547.49 (+6.48), ORCL: 40.45 (+0.51), NVS: 92.63 (+0.87)
3 Biotech Stocks to Watch in November
Motley Fool Staff - Motley Fool - Sat Nov 08, 10:03AM CST
Investing in biotech companies can be tricky, especially for investors who don't have a scientific background or who don't completely understand the process of bringing new drugs to the marketplace. Fortunately, the Fool is here to help. We asked...
AVNR: 13.22 (+0.20), SGEN: 36.90 (+0.85), GILD: 107.02 (+0.57), ABBV: 63.79 (+2.29), GSK: 45.16 (+0.25)
Gilead (GILD) Submits HIV Combination Drug for FDA Review - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 5:50PM CST
Gilead Sciences, Inc. announced that it has submitted a New Drug Application to the FDA for its tenofovir alafenamide-based single tablet regimen.
AGN: 195.24 (-0.76), JNJ: 108.82 (+0.62), GILD: 107.02 (+0.57), ABBV: 63.79 (+2.29)
Novartis' (NVS) LBH589 Gets Unfavorable FDA Panel Opinion - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 4:20PM CST
Novartis (NVS) received disappointing news when the FDA's Oncologic Drugs Advisory Committee (ODAC) did not recommend its pipeline candidate LBH589.
AGN: 195.24 (-0.76), ABBV: 63.79 (+2.29), BMY: 58.81 (+0.49), NVS: 92.63 (+0.87)
AstraZeneca (AZN) Misses on Q3 Earnings, Raises Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 2:20PM CST
AstraZeneca (AZN) reported third-quarter 2014 core earnings of $1.05 per ADS that missed the Zacks Consensus Estimate by a penny.
AGN: 195.24 (-0.76), AZN: 73.21 (+0.33), ABBV: 63.79 (+2.29), AEGR: 21.57 (-0.01)
One Factor Driving AbbVie (ABBV) Stock Down Today
at The Street - Fri Nov 07, 10:50AM CST
Shares of AbbVie (ABBV) are down after the company was downgraded to 'market perform' to 'outperform' at BMO Capital Markets earlier on Friday.
ABBV: 63.79 (+2.29)
SurModics Beats on Q4 Earnings, Issues Fiscal 2015 Outlook - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 9:10AM CST
SurModics, Inc.???s fourth-quarter fiscal 2014 adjusted earnings of 26 cents per share beat the Zacks Consensus Estimate by a penny.
AGN: 195.24 (-0.76), SRDX: 20.86 (+0.42), ABAX: 52.94 (+1.31), ABBV: 63.79 (+2.29)
Why AbbVie Inc.'s Game-Changing New Drug Could Be a Serious Threat to Gilead Sciences Inc.
George Budwell, The Motley Fool - Motley Fool - Fri Nov 07, 7:45AM CST
The patent cliff might have decimated revenues in the world of Big Pharma, but it has also led to an unprecedented level of innovation within the industry. In the coming years, for example, we should see four to five new types of drugs that are...
JNJ: 108.82 (+0.62), ESRX: 77.99 (+0.12), GILD: 107.02 (+0.57), ABBV: 63.79 (+2.29), BMY: 58.81 (+0.49), ENTA: 44.14 (+0.81)
Global Cognitive Impairment Therapeutics Pipeline Review 2014 - 53 Drug Profiles from 23 Leading Pharma Companies
M2 - Fri Nov 07, 6:02AM CST
Research and Markets (http://www.researchandmarkets.com/research/jxpc52/cognitive) has announced the addition of the "Cognitive Impairment - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cognitive Impairment, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cognitive Impairment and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bristol-Myers Squibb Company - F. Hoffmann-La Roche Ltd. - AstraZeneca PLC - Merck & Co., Inc. - Panacea Pharmaceuticals, Inc. - Pfizer Inc. - Teva Pharmaceutical Industries Limited - Shire Plc - Evotec AG - Suven Life Sciences Ltd. - AGY Therapeutics, Inc. - Cardax Pharmaceuticals, Inc. - Siena Biotech S.p.A. - Virogenomics, Inc. - Dart NeuroScience LLC - Omeros Corporation - Intra-Cellular Therapies, Inc. - Heptares Therapeutics Ltd. - Pacific Northwest Biotechnology, LLC - Vicore Pharma AB - Pherin Pharmaceuticals, Inc. - AbbVie Inc. - Saniona AB For more information visit http://www.researchandmarkets.com/research/jxpc52/cognitive
SHPG: 200.98 (+2.40), PFE: 30.20 (+0.28), MRK: 58.81 (-0.53), AZN: 73.21 (+0.33), TEVA: 58.04 (+0.34), ITCI: 15.74 (+0.48), ABBV: 63.79 (+2.29), BMY: 58.81 (+0.49), OMER: 17.49 (+0.12)
